Cleveland BioLabs Receivables

Cleveland BioLabs (CBLI) currently reports a receivables of $0 as of June 2021. That compares with $250K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Cleveland BioLabs's receivables history and peer comparisons.

Cleveland BioLabs's receivables decreased from $250K to $0 — a 100.0% year-over-year decrease (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cleveland BioLabs reported $0 in receivables as of June 2021. That compares with $250K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cleveland BioLabs, and consider following CBLI for alerts when major investors trade the stock.

Cleveland BioLabs is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBLI with unrelated industries.